nasdaq:rdhl
|
2259672
|
Apr 14th, 2024 12:00AM
|
RedHill Biopharma Ltd.
|
6.1K
|
78.00
|
Open
|
|
Apr 13th, 2024 11:37PM
|
Apr 13th, 2024 11:37PM
|
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases.
RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S.
RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.
RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification.
RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
|
Open
|
|
Open
|
8045 Arco Corporate Drive
|
Raleigh
|
NC
|
US
|
27617
|
|
Redhill Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:rdhl
|
2259672
|
Apr 13th, 2024 12:00AM
|
RedHill Biopharma Ltd.
|
6.1K
|
78.00
|
Open
|
|
Apr 12th, 2024 11:28PM
|
Apr 13th, 2024 12:02PM
|
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases.
RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S.
RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.
RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification.
RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
|
Open
|
|
Open
|
8045 Arco Corporate Drive
|
Raleigh
|
NC
|
US
|
27617
|
|
Redhill Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:rdhl
|
2259672
|
Apr 12th, 2024 12:00AM
|
RedHill Biopharma Ltd.
|
6.1K
|
78.00
|
Open
|
|
Apr 11th, 2024 11:35PM
|
Apr 12th, 2024 08:57AM
|
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases.
RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S.
RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.
RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification.
RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
|
Open
|
|
Open
|
8045 Arco Corporate Drive
|
Raleigh
|
NC
|
US
|
27617
|
|
Redhill Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:rdhl
|
2259672
|
Apr 11th, 2024 12:00AM
|
RedHill Biopharma Ltd.
|
6.1K
|
78.00
|
Open
|
|
Apr 11th, 2024 12:07AM
|
Apr 11th, 2024 11:43AM
|
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases.
RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S.
RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.
RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification.
RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
|
Open
|
|
Open
|
8045 Arco Corporate Drive
|
Raleigh
|
NC
|
US
|
27617
|
|
Redhill Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:rdhl
|
2259672
|
Apr 10th, 2024 12:00AM
|
RedHill Biopharma Ltd.
|
6.1K
|
78.00
|
Open
|
|
Apr 9th, 2024 11:36PM
|
Apr 10th, 2024 05:50PM
|
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases.
RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S.
RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.
RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification.
RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
|
Open
|
|
Open
|
8045 Arco Corporate Drive
|
Raleigh
|
NC
|
US
|
27617
|
|
Redhill Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:rdhl
|
2259672
|
Apr 9th, 2024 12:00AM
|
RedHill Biopharma Ltd.
|
6.1K
|
78.00
|
Open
|
|
Apr 8th, 2024 11:47PM
|
Apr 9th, 2024 10:32AM
|
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases.
RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S.
RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.
RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification.
RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
|
Open
|
|
Open
|
8045 Arco Corporate Drive
|
Raleigh
|
NC
|
US
|
27617
|
|
Redhill Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:rdhl
|
2259672
|
Apr 8th, 2024 12:00AM
|
RedHill Biopharma Ltd.
|
6.1K
|
79.00
|
Open
|
|
Apr 8th, 2024 12:15AM
|
Apr 8th, 2024 07:29PM
|
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases.
RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S.
RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.
RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification.
RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
|
Open
|
|
Open
|
8045 Arco Corporate Drive
|
Raleigh
|
NC
|
US
|
27617
|
|
Redhill Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:rdhl
|
2259672
|
Apr 7th, 2024 12:00AM
|
RedHill Biopharma Ltd.
|
6.1K
|
79.00
|
Open
|
|
Apr 6th, 2024 11:42PM
|
Apr 6th, 2024 11:42PM
|
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases.
RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S.
RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.
RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification.
RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
|
Open
|
|
Open
|
8045 Arco Corporate Drive
|
Raleigh
|
NC
|
US
|
27617
|
|
Redhill Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:rdhl
|
2259672
|
Apr 6th, 2024 12:00AM
|
RedHill Biopharma Ltd.
|
6.1K
|
79.00
|
Open
|
|
Apr 5th, 2024 11:42PM
|
Apr 5th, 2024 11:42PM
|
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases.
RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S.
RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.
RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification.
RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
|
Open
|
|
Open
|
8045 Arco Corporate Drive
|
Raleigh
|
NC
|
US
|
27617
|
|
Redhill Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|
nasdaq:rdhl
|
2259672
|
Apr 5th, 2024 12:00AM
|
RedHill Biopharma Ltd.
|
6.1K
|
79.00
|
Open
|
|
Apr 5th, 2024 12:17AM
|
Apr 5th, 2024 12:17AM
|
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal diseases and infectious diseases.
RedHill’s U.S. commercial operations, headquartered in Raleigh, NC, include a gastrointestinal-focused sales force promoting several specialty gastrointestinal products in the U.S.
RedHill’s pipeline includes several drug candidates in advanced clinical development stages addressing clear medical needs and aiming to relieve suffering and save lives. RedHill’s drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development.
RedHill’s products are based on several technology platforms and address several disease targets, thus providing for risk diversification.
RedHill’s experienced management team, board of directors and advisory board, based in Israel, the U.S., Canada and Europe, comes with a successful track record of bringing patented drugs to the market, as well as extensive managerial, financial, and transactional expertise.
|
Open
|
|
Open
|
8045 Arco Corporate Drive
|
Raleigh
|
NC
|
US
|
27617
|
|
Redhill Biopharma
|
Health Care
|
Pharmaceuticals & Biotechnology
|